Determine the necessary mass, volume, or concentration for preparing a solution.
2mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 4 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Information
In vitro
Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi humancolon cancer cells andMDA MB-468 human breast cancer cells. Erlotinib HCl (1 μM) induces apoptosis in DiFi humancolon cancer cells. Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM. Erlotinib HCl(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells. The effects of Erlotinib HCl in combination with gemcitabine are considered additive in KRAS-mutated pancreatic cancer cells. Ten micromolar of Erlotinib HCl inhibits EGFR phospho-rylation at the Y845 (Src-dependent phosphorylation) and Y1068 (auto-phosphorylation) sites. Combination with Erlotinib HCl could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition.
In vivo
At doses of 100 mg/kg, Erlotinib HCl completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice. Erlotinib HCl (100 mg/Kg) inhibits H460a and A549 tumor models with 71 and 93% inhibition rate.
Cell Data
cell lines:
Concentrations:30 nM-20 μM
Incubation Time:72 hours
Powder Purity:≥99%
| Isomeric SMILES | COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC.Cl |
|---|---|
| Alternate CAS | 183319-69-9 |
| NSC Number | 718781 |
| MeSH Entry Terms | 11C erlotinib;11C-erlotinib;358,774, CP;358774, CP;CP 358,774;CP 358774;CP-358,774;CP-358774;CP358,774;CP358774;erlotinib;erlotinib HCl;erlotinib hydrochloride;HCl, Erlotinib;Hydrochloride, Erlotinib;N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin- |
| Molecular Weight | 429.9 |
| Reaxy-Rn | 8813963 |
| Reaxys-RN_link_address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=8813963&ln= |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubility | Solubility (25°C) In vitro DMSO: 75 mg/mL (293.8 mM); Water: 75 mg/mL (293.8 mM); Ethanol: 75 mg/mL warmed with 50ºC Water: bath (293.8 mM); |
|---|---|
| Melt Point(°C) | 228 °C |
| 1. Yun Zheng, Qiong Zhao, Jing Lin, Xiaoyang Dai, Chenyu Zhu, Yujie Wang, Hongye Fu. (2022) Xijiao Dihuang decoction relieves the erlotinib-induced dermatitis. EXPERIMENTAL CELL RESEARCH, [PMID:36435221] [10.1016/j.yexcr.2022.113437] |
| 2. Yuping Liu, Xiangliang Jiang, Yue Gu, Yan Chen. (2019) Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor. INTERNATIONAL IMMUNOPHARMACOLOGY, [PMID:30682720] [10.1016/j.intimp.2019.01.023] |
| 3. Yueying Zhang, Dan Gao, Shangfu Li, Weili Wei, Jinshun Lin, Yuyang Jiang. (2019) 1,5-Diaminonaphthalene functionalized carbon nanodots as a novel matrix for the analysis of small molecules by matrix-assisted laser desorption/ionization mass spectrometry. Analytical Methods, 11 (8): (1131-1136). [PMID:] [10.1039/C8AY02665C] |
| 4. Xiaolan Zhou, Xiaofeng Zhu, Weixu Wang, Jing Wang, Haimei Wen, Yuqi Zhao, Jiayu Zhang, Qiushi Xu, Zhaozhao Zhao, Ting Ni. (2025) Comprehensive Cellular Senescence Evaluation to Aid Targeted Therapies. Research, [PMID:39822281] [10.34133/research.0576] |